Abbott India Limited has announced the appointment of Ms. Swati Pathak as the Associate Director - Operations. The appointment is effective June 1, 2026, and was approved by the company's Board of Directors based on the recommendation of the Nomination and Remuneration Committee. Ms. Pathak will serve as part of the Senior Management team of abbott .

Ms. Pathak possesses over 22 years of professional experience. Most recently, she led the New Product Introduction (NPI) & Therapy Area Strategy (TAS) function for Abbott's Specialty Care business in India. In this capacity, she established NPI as a key growth engine, ensuring the timely launch of multiple products across various therapy areas. Her efforts included lifecycle management initiatives and the development of a robust pipeline to support sustained growth.

She joined Abbott in 2007 as a Research Scientist in Innovation and Development (I&D). She subsequently transitioned into Project Management in 2010 and later served in Portfolio Strategy roles until 2022. Throughout her tenure, she has been a key contributor to Abbott's I&D transformation, acting as a strategic partner to drive incremental growth and deliver critical revenue through strong project execution. Additionally, she played a pivotal role in establishing and institutionalizing Project Management Office (PMO) processes within I&D and led several major NPI launches across Abbott's pharmaceutical business in India.

Prior to her tenure at Abbott, Ms. Pathak worked with Ipca R&D for four years as a formulation development scientist focusing on the US and EU markets. She holds a Bachelor's degree in Pharmacy from Pune University and a postgraduate qualification in Bioinformatics and Patent Law from NALSAR, Hyderabad. Her contributions to innovation and delivery excellence have been recognized with multiple prestigious awards, including the VP Award, Da Vinci Award, and MD Awards.

The company confirmed that Ms. Swati Pathak is not related to any of the Directors, Key Managerial Personnel, or Senior Management of the Company. The appointment was communicated to the stock exchanges in compliance with Regulation 30 of the SEBI Listing Regulations.

Appointment Details

Abbott India Limited 's Board of Directors, at its meeting held on May 11, 2026, approved the audited financial results for the quarter and financial year ended March 31, 2026. The results were prepared in accordance with Indian Accounting Standards (Ind AS) under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and carry an unmodified audit opinion from statutory auditors M/s. Walker Chandiok & Co. LLP. Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company intimated BSE Limited on May 13, 2026, that the audited financial results for the quarter and financial year ended March 31, 2026 were published in Business Standard (All Editions) and Loksatta (Mumbai) on Wednesday, May 13, 2026. The intimation was signed by Company Secretary Sangeeta Shetty (Membership No.: ACS 18865).

Financial Performance: FY26 vs FY25

Abbott India delivered a strong financial performance for the full year ended March 31, 2026. Revenue from operations grew to Rs. 6,929.05 crores from Rs. 6,409.15 crores in the previous year, while total income rose to Rs. 7,217.19 crores from Rs. 6,684.73 crores. Net profit for the year stood at Rs. 1,552.02 crores, compared to Rs. 1,414.44 crores in FY25. The following table summarises the key financial metrics:

Quarterly Performance: Q4 FY26

For the quarter ended March 31, 2026, Abbott India reported revenue from operations of Rs. 1,709.51 crores, compared to Rs. 1,604.59 crores in the corresponding quarter of the previous year. Profit before tax for the quarter stood at Rs. 531.23 crores versus Rs. 482.71 crores in Q4 FY25, while net profit came in at Rs. 394.93 crores against Rs. 367.04 crores. The basic/diluted earnings per share for the quarter was Rs. 185.85. On an operational efficiency basis, Q4 EBITDA stood at Rs. 4.8B versus Rs. 4.3B in the same quarter last year, with the EBITDA margin expanding to 28.09% from 26.73% year-on-year.

Dividend Declaration and Key Corporate Dates

The Board recommended a final dividend of Rs. 525 and a special dividend of Rs. 131 per equity share of Rs. 10 each for the financial year ended March 31, 2026, aggregating to Rs. 656 per share. This compares to a final dividend of Rs. 475 per equity share declared for the year ended March 31, 2025. The dividend is subject to approval by shareholders at the forthcoming Annual General Meeting. Key dates related to the dividend and AGM are as follows:

Balance Sheet and Cash Flow Highlights

As at March 31, 2026, Abbott India's total assets stood at Rs. 6,501.93 crores, up from Rs. 5,917.31 crores as at March 31, 2025. Total equity increased to Rs. 4,774.19 crores from Rs. 4,233.15 crores. Cash and cash equivalents at the end of FY26 were Rs. 442.33 crores, compared to Rs. 560.59 crores at the start of the year. Net cash flows generated from operating activities for FY26 amounted to Rs. 1,319.24 crores, against Rs. 1,011.84 crores in FY25.

Other Corporate Developments

The Board also approved the appointment of M/s. Kishore Bhatia & Associates, Cost Accountants (Firm Registration No. 00294), as Cost Auditors of the company for the financial year 2026-27, subject to ratification of remuneration by members at the Eighty-second AGM. Additionally, the company recognised an incremental cost of Rs. 18.10 crores as part of employee benefit expenses during FY26, following its assessment of the implications of the four New Labour Codes notified by the Government of India on November 21, 2025. The company operates in a single business segment — Pharmaceuticals. Mr. Munir Shaikh (DIN: 00096273), who was liable to retire by rotation at the forthcoming AGM, has not offered himself for re-appointment.